GAS-Luc2 Reporter Cancer Cell Lines Demonstrating Superior Performance to the Industrial Standard Interferon-gamma ELISA in 2-D and 3-D Ex Vivo Immune Activation and Drug Screening
AACR Annual Meeting 2025
Chicago, Illinois, United States
April 29, 2025Abstract
Download the poster to learn about our immune activation reporter cancer cell lines.
DownloadPresenter
Hyeyoun Chang, PhD
Scientist, ATCC
Hyeyoun Chang, PhD, is a Scientist in the Immuno-oncology group of the R&D department at ATCC. She has extensive experience in the fields of biomedical engineering and cancer biology that focuses on drug delivery, intracellular signaling, and gene therapy. Prior to joining ATCC, Dr. Chang received her PhD in biomedical engineering from Korea University of Science and Technology and completed her postdoctoral training at Dana-Farber Cancer Institute/ Harvard Medical School.
Immuno-oncology reporter models
Cancer immunotherapy has emerged as an exciting new approach for cancer treatment, and immuno-oncology is one of the fastest growing fields in oncology.
The development of immunomodulatory drugs and biologics dictates a clear need for human cell-based models to evaluate immune activation. To answer this need, ATCC provides a growing collection of reporter models, including checkpoint luciferase reporter cells, CAR-T luciferase reporter cells, and THP-1 reporter cells.
Explore immuno-oncology reporter models